Our findings suggest that therapeutic strategies targeting the FOXM1–KIF4A axis can be useful for the treatment of HCC and possibly other cancers that are characterized by FOXM1 overexpression. This evidence concerns the gene KIF4A and hepatocellular carcinoma.